CNS Pharmaceuticals, Inc. CNSP
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -4.76%
- 1 year
- -33.42%
- Open
- 4.60
- Prev close
- 4.77
- Mkt cap
- 7.31M
- Vol
- 52.92K
- Avg vol
- 9.02K
- EPS
- -17.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.25
- High
- 5.00
- Forward P/E
- -0.28
- Beta
- 1.05
- Short ratio
- 0.04
- Inst. own
- 0.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.11872
- 200-d avg
- 4.42
- 1y target
- 0.50
Key statistics
- Market cap
- 6.27M
- Enterprise value
- 2.01M
- Trailing P/E
- 0.00
- Forward P/E
- -0.28
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -299.06
- Beta
- 1.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -5.19M
- Total cash
- 1.49M
- Total debt
- 123.25K
- Return on equity
- 0.00%
- Shares outstanding
- 57.49M
- Short % of float
- 2.79%
- 50-day average
- 0.11872
- 200-day average
- 4.42
Analyst view
Consensus: none
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.25 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -6.72 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -20.50 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -47.50 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -54.00 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -52.00 | — | — |
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cnspharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CNSP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLIMACO JOHN M | Chief Executive Officer | Purchase | Jan 31, 2024 | 215,676 |
| DOWNS CHRISTOPHER | Chief Financial Officer | Purchase | Jan 31, 2024 | 103,438 |
| EVANS CARL ANTHONY | Director | Purchase | Jan 31, 2024 | 33,458 |
| GUMULKA JERZY | Director | Purchase | Jan 31, 2024 | 43,006 |
| PRIEBE WALDEMAR PH.D. | Beneficial Owner of more than 10% of a Class of Security | Sale | Mar 27, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.35% | 203,180 | 22.15K | Sep 29, 2024 |
| UBS Group AG | 0.32% | 181,866 | 19.82K | Sep 29, 2024 |
| Virtu Financial LLC | 0.21% | 122,876 | 13.39K | Sep 29, 2024 |
| Goldman Sachs Group Inc | 0.05% | 28,197 | 3.07K | Sep 29, 2024 |
| Jane Street Group, LLC | 0.04% | 23,160 | 2.52K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 16,298 | 1.78K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.28% | 162,183 | 17.68K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 37,943 | 4.13K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 1,168 | 127 | Sep 29, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 8 | 0 | Sep 29, 2024 |